CRAD-B.STCRAD-B.STSTO
Loading
C-Rad AB is a Swedish medical device company specializing in surface-guided radiation therapy (SGRT) systems and patient positioning solutions for oncology departments. The company's Catalyst and Sentinel products enable real-time tumor tracking and patient motion management during radiation treatment, competing in a niche but growing segment of radiation oncology equipment. With 69% gross margins but declining revenue (-5.8% YoY) and compressed net margins (2.4%), the company faces execution challenges despite strong FCF generation.
C-Rad generates revenue through upfront capital equipment sales to hospitals and cancer treatment centers (typically $100K-$300K per system), followed by recurring service contracts and software maintenance fees. The company's competitive advantage lies in its optical surface scanning technology that provides real-time 3D patient positioning without ionizing radiation, integrated with major linear accelerator manufacturers (Varian, Elekta). Pricing power is moderate as customers evaluate against competitors like Vision RT and AlignRT, with purchasing decisions driven by clinical outcomes data and integration capabilities. The installed base of several hundred systems globally provides a foundation for recurring revenue, though capital equipment sales remain the primary driver.
New system orders and backlog trends from major cancer centers in Europe and North America
Regulatory approvals and clinical adoption in new geographic markets (particularly US expansion)
Competitive wins against Vision RT in large hospital network RFPs
Recurring revenue growth rate from installed base indicating customer retention and upgrade cycles
Partnership announcements with linear accelerator OEMs (Varian/Siemens, Elekta) for bundled offerings
Technological disruption from AI-based patient positioning systems or alternative motion management technologies that could commoditize optical surface scanning
Consolidation among linear accelerator manufacturers (Varian acquired by Siemens) could shift competitive dynamics if OEMs develop in-house SGRT capabilities
Reimbursement policy changes in key markets that reduce incentives for advanced radiation therapy techniques requiring surface guidance
Vision RT (AlignRT) maintains strong market position with established clinical evidence and broader installed base, particularly in North America
Price compression as SGRT technology matures and becomes table-stakes rather than premium offering, pressuring gross margins
Large medical device conglomerates (Siemens Healthineers, Philips) could enter the market through acquisition or internal development, leveraging existing hospital relationships
Revenue decline of 5.8% YoY and net income drop of 81.4% indicate execution challenges that could pressure cash generation if trends continue
Small market cap ($0.9B) and limited trading liquidity create vulnerability to investor sentiment shifts and difficulty raising capital if needed
Geographic concentration risk if European hospital budgets face sustained pressure from fiscal constraints or healthcare system reforms
moderate - Hospital capital equipment budgets exhibit some cyclicality but are more resilient than discretionary consumer spending. Cancer treatment volumes are relatively stable through economic cycles, but hospital purchasing decisions can be delayed during budget constraints or credit tightening. The company's exposure to European and North American healthcare systems provides some diversification, though public hospital budgets in Europe can face pressure during fiscal austerity periods.
Rising interest rates have moderate negative impact through two channels: (1) hospital capital budgets face higher financing costs for equipment purchases, potentially extending sales cycles or reducing order sizes, and (2) as a growth-stage company trading at 2.0x sales, higher discount rates compress valuation multiples. However, the company's minimal debt (0.05 D/E) insulates it from direct financing cost pressures. The strong current ratio of 3.09 suggests adequate liquidity regardless of rate environment.
Low direct exposure. The company's customers are primarily established hospitals and cancer centers with stable credit profiles. Receivables risk is limited given the institutional customer base. However, tighter credit conditions could indirectly impact hospital capital expenditure budgets and delay purchasing decisions, particularly for mid-tier regional hospitals that may rely on equipment financing.
value - The stock trades at 2.0x sales with 7.9% FCF yield despite negative momentum, attracting value investors betting on operational turnaround and return to growth. The 69% gross margins and strong balance sheet (3.09 current ratio, minimal debt) provide downside protection. However, the -81% net income decline and negative price momentum have driven away growth investors. The profile suits contrarian value investors with 12-24 month time horizons willing to wait for revenue stabilization and margin recovery.
high - Small-cap medical device stocks with lumpy capital equipment sales exhibit elevated volatility. The -19.3% three-month return and -20.0% six-month return demonstrate significant downside volatility. Limited analyst coverage and trading liquidity on Stockholm exchange amplify price swings on quarterly results. Beta likely exceeds 1.3-1.5 relative to Swedish healthcare index.